Asia FX dithers as dollar steadies before Powell speech; yen muted after CPI data
Roger Adsett, Chief Operating Officer of Insmed Inc. (NASDAQ:INSM), recently sold a substantial amount of company stock. According to an SEC filing, Adsett sold a total of 43,975 shares on February 10, 2025, with a total transaction value of approximately $3.38 million. The sale comes as Insmed’s stock trades near its 52-week high of $82.04, having delivered an impressive 187% return over the past year. InvestingPro analysis indicates the stock is currently trading above its Fair Value. The shares were sold at prices ranging from $77.02 to $79.33 per share. Following these transactions, Adsett retains ownership of 146,082 shares in the company. The sales were executed as part of a pre-established 10b5-1 trading plan. With Insmed’s market capitalization now at $14.24 billion and its next earnings report due on February 20, investors can access comprehensive insider trading analysis and 12 additional key insights through InvestingPro’s detailed research reports.
In other recent news, Insmed Incorporated has seen significant developments. Stifel analysts maintained their Buy rating on Insmed shares and raised the price target from $88.00 to $97.00, reflecting confidence in the company’s future, especially concerning the potential launch of brensocatib. The U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New Drug Application (NDA) for brensocatib, a potential treatment for non-cystic fibrosis bronchiectasis, with a target action date set for August 12, 2025.
Truist Securities also maintained a Buy rating on Insmed shares, keeping the price target steady at $105.00. The firm highlighted several upcoming catalysts for the company, including the potential of brensocatib and the TPIP program, expected to show Phase 2 topline data for pulmonary arterial hypertension (PAH) in mid-2025. Insmed reported preliminary sales of its drug Arikayce for the fiscal year 2024, surpassing both the company’s guidance and consensus estimates, and projected global revenues for Arikayce in fiscal year 2025 to reach between $405 million and $425 million.
However, Insmed terminated a significant sales agreement with Leerink Partners LLC, which allowed Insmed to sell up to $500 million of its common stock through Leerink. The termination was effective immediately, with no penalties incurred by Insmed. Despite this, both Stifel and Truist Securities maintain a positive outlook on Insmed’s future prospects, grounded in the company’s strong pipeline and the significant milestones expected in the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.